Table 5.
The characteristics of the allotransplant recipients and their donors included in the analysis.
| Recipients (n = 85) | Characteristics |
|---|---|
| Age, median and range (Years) | 47 (18–70) |
| Diagnosis (number) | |
| AML, de novo | 37 |
| AML secondary to myelodysplastic syndrome | 17 |
| Myelodysplastic syndrome, high-risk | 2 |
| Acute lymphoblastic leukemia | 15 |
| Chronic myeloid leukemia | 3 |
| Myelofibrosis/Myeloproliferative neoplasia, unspecified | 6 |
| Chronic myelomonocytic leukemia | 2 |
| Chronic lymphocytic leukemia | 2 |
| Hodgkin’s lymphoma | 1 |
| Leukemia patients not in remission at transplantation | 1 |
| aGVHD requiring high dose steroid treatment (number) 1 | 38 |
| Conditioning regimes (number) | |
| Busulfan + cyclophosphamide (myeloablative condition) | 66 |
| Fludarabine + busulfan (reduced intensity conditioning) | 16 |
| Others | 3 |
| Stem cell source (number) | |
| Peripheral blood mobilized stem cells | 85 |
| Bone marrow grafts | 0 |
| DONORS (n = 85) | |
| Sibling/other family donors | 78/7 |
| Female/Male | 54/31 |
| Age; median (range) | 49 (18–77) |
| Female donor to male recipient | 19 |
| Number of CMV positive recipients | 60 |
| CMV positive donor to CMV negative recipient | 15 |
1 The criteria for receiving high-dose systemic steroid treatment were acute GVHD grade II with gastrointestinal involvement or Grade III/IV acute GVHD.